David Rees AM calls for transformation of care for IPF patients

Following a British Lung Foundation (BLF) held reception on 01 October at the National Assembly for Wales, David Rees is backing the call to transform the care for IPF patients.

IPF is a disease that causes a gradual scarring of the lungs which has been on the rise in the UK for decades. It now kills over 5,000 people a year – more than conditions such as leukaemia1,2 . However, awareness remains low, and there is no known cause or cure. As a result, the disease acts with often-devastating speed: barely half of people diagnosed with IPF are still alive three years later.

David said: “Attending the reception has made me determined to do all I can to help those in Aberavon who are affected by IPF. I will be calling for funding to be made available, seeking assurances that there is accessible information about IPF at the point of diagnosis for patients, and for patients to have access to a named specialist nurse so we can transform the lives of those living with IPF.”

To find out more about IPF visit www.blf.org.uk/IPF



SUBSCRIBE FOR EMAIL UPDATES
Keep Updated
Subscribe to my email newsletter to get the latest news on Welsh Government investment and my campaigns in Aberavon.
Subscribe
I agree to the Privacy Policy and to receive email updates.
SUBSCRIBE FOR EMAIL UPDATES
Keep Updated
Subscribe to my email newsletter to get the latest news on Welsh Government investment and my campaigns in Aberavon.
Subsribe
I agree to the Privacy Policy and to receive email updates.
We use cookies to improve your overall site experience. This includes personalising content, analysing site usage, and to assist in our marketing efforts. By continuing to use our site, you accept our use of cookies and Privacy Policy.
Contact Details
Privacy Policy
Accept
We use cookies to improve your overall site experience. This includes personalising content, analysing site usage, and to assist in our marketing efforts. By continuing to use our site, you accept our use of cookies and Privacy Policy.
Accept